Displaying drugs 5676 - 5700 of 5845 in total
C31G
C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV).
Investigational
CP-122721
CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
Investigational
INO-1001
Investigational
GTS-21
GTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity in human clinical trials. Athenagen licensed the exclusive rights to the compound and a related library of analogs as part of the acquisition...
Investigational
Pegnivacogin
Investigational
Mirostipen
Investigational
Squalamine
Investigational
Taberminogene vadenovec
Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after vascular surgery. The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have...
Investigational
XL228
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
NVS antibody
This drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.
Investigational
NAV 1800
RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal cancer.
Investigational
Pelitinib
Pelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
Investigational
TRU-015
Investigational
PRX-03140
Investigational
AI-850
AI-850 is a Cremophor(R)-free formulation of paclitaxel, the active ingredient in Taxol(R), a product used to treat a variety of solid tumors.
Investigational
CERE-110
CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. This drug is developed by Ceregene and currently under phase I of clinical trial.
Investigational
EGEN-001
EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity.
Investigational
ACY001
Investigational
Tarazepide
Investigational
Resiniferatoxin
Resiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission of physiological pain).
Investigational
Labradimil
Investigational
CTCE-0214
CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood cells.
Investigational
Glufosfamide
Investigational
Atiprimod
Investigational
Mx-dnG1
Investigational
Displaying drugs 5676 - 5700 of 5845 in total